Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed cutaneous T-cell lymphoma
• •* Stage IB-IV disease
• •Measurable disease
• •Newly diagnosed or previously treated disease
• •* No demonstrated resistance to prior bexarotene
• •PATIENT CHARACTERISTICS:
• •Performance status
• •Karnofsky 60-100%
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• •Bilirubin \< 1.5 times ULN
• •Renal
• •Creatinine ≤ 1.5 times ULN
• •Cardiovascular
• •Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram
• •No New York Heart Association class II-IV heart disease
• •No clinical evidence of congestive heart failure
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment
• •No history of hypersensitivity reactions attributed to doxorubicin HCl liposome or its components
• •No active potentially life-threatening infection
• •No other acute disease
• •PRIOR CONCURRENT THERAPY:
• •Chemotherapy
• •See Disease Characteristics
• •Prior doxorubicin allowed provided the cumulative dose is ≤ 300 mg/m\^2
• •Prior epirubicin hydrochloride allowed provided the cumulative dose is ≤ 540 mg/m\^2